N1VS34
R$66.82
0.00%
Stock
Novartis AG
Official Company Name: Novartis AG
Stock Symbol: N1VS34
Stock Market: B3 - Bovespa
Currency: Brazilian real - BRL
N1VS34 Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▲+10.48%
Daily closing prices, with moving averages and volumes - Brazilian real (BRL)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Switzerland
Company Description
Novartis AG is a global healthcare company that researches, develops, manufactures, and markets healthcare products. It operates through two segments: Innovative Medicines, offering prescription drugs across various therapeutic areas, and Sandoz, which develops, manufactures, and markets finished dosage form medicines, and provides active pharmaceutical ingredients, biosimilars, and biotechnology manufacturing services. Novartis collaborates with various entities to enhance its product offerings.
N1VS34 Stock Data
| Open | R$66.82 |
| High | R$66.82 |
| Low | R$66.82 |
| Close | R$66.82 |
| Volume | 0 |
| Previous Close | R$66.82 |
| 1-Day Change | 0.00 |
| 1-Year Change | 6.34 |
| Average Daily Volume | 205 |
| 52-Week High | R$68.22 |
| 52-Week Low | R$58.33 |
Ratios as of Jan. 25, 2025
| Beta | 0.51 |
| Trailing PE | 16.94 |
| Forward PE | 14.03 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.